Jean-Paul Borg
  • E-mail :[email]
  • Phone : 04 86 97 72 01
  • Location : Marseille, France
Last update 2016-08-26 17:20:42.198

Jean-Paul Borg PharmD, PhD (Immunology)

Course and current status

2011           Appointed PU-PH

2006-…      Appointed Full Professor at the Université de la Méditerranée

                     Scientific Director of Institut Paoli-Calmettes

 2006           Senior Investigator INSERM 1st class (DR1 Inserm)

2002-05     Senior Investigator INSERM (2nd class), INSERM Marseille

2004         Group Leader at Inserm 

1998-2002 Investigator INSERM (1st class), U119 INSERM Marseille, France

1995-1998  Research Fellow at Howard Hughes Medical Institute, Ann Arbor, Michigan USA

1992-1995  PhD in Immunology at U119 INSERM Marseille, France

1984-1995   PharmD and DES Biologie Médicale, (Marseille)

1991          Master in Immunology at CIML, Marseille


Scientific summary

Doctor in Pharmacy (1995, Marseille), PhD in Immunology (1995, Marseille, D. Birnbaum’s lab), Jean-Paul Borg was a post-doctoral fellow at Howard Hughes Medical Institute (Ann Arbor, MI, USA, Ben Margolis’s lab) from 1995 to 1998. From 1998 to 2006, he was an INSERM Investigator and then became Professor of Cell Biology at Aix-Marseille University (since 2006). He is Head of the “Cell Polarity, Cell Signalling and Cancer” team at CRCM since 2004 (team ranked A+ by the French Agency for Evaluation of Research and Teaching in 2011) and Director of CRCM since 2012. Since 2007, he is the Scientific Director of Institut Paoli-Calmettes, one of the largest university-affiliated comprehensive cancer centers in France, and Head of the Department of Pathology. He is also co-coordinator of the Marseille Proteomic Platform labelled IBiSA since 2008 and senior member of Institut Universitaire de France. The major part of his scientific career has been focused on elucidating cell signalling pathways (tyrosine kinases, WNT) and molecular networks centred on cell polarity proteins in the field of cancer. His latest discoveries are related to non-canonical WNT pathway in breast cancer.

Image d’exemple